MedTrace Logo

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

NCT06418412 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-06-12

No results posted yet for this study

Summary

There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies.

This study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.

Conditions

  • Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer

Sponsors & Collaborators

  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • Aaron C. Tan, MBBS, PhD · National Cancer Centre, Singapore

  • Daniel SW Tan, BSc, MBBS, PhD · National Cancer Centre, Singapore

  • Dong-Wan Kim, MD, MS, PhD · Seoul National University Hospital

  • Jin-Yuan Shih, MD, PhD · National Taiwan University Hospital

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Singapore
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06418412 on ClinicalTrials.gov